Navigation Links
RxTrials Announces Hiring Adam Chasse as VP of Business Development
Date:5/11/2011

ELLICOTT CITY, Md., May 11, 2011 /PRNewswire/ -- Christine Pierre, president of RxTrials, Inc., today named Adam Chasse vice president of business development. Chasse, who has been head of prime sites for Quintiles, will begin on May 11 and be based in Triangle Park, North Carolina.

"I have collaborated with Adam for 16 years and have admired what he has accomplished personally and for his employer, but what really stands out for me is his integrity. Yes, he brings a global perspective and valuable experience gained by working for the largest contract research organization in the world, but, more importantly, he brings a vision for the future of our organization that is closely aligned with that of our other top managers," said Pierre.

Chasse has served on the board of advisors for the Site Solutions Summit since its inception seven years ago. The Summit is an annual industry meeting organized by RxTrials Institute and focused on research sites' best practices. RxTrials Institute is an RxTrials affiliate.

"Quite frankly he was my first choice; I've been asking him for about five years when he was going to come to the other side and join the sites world," said Pierre with a smile.

"I'm very, very excited because I've always admired RxTrials for its history of delivery and quality, and its forward-thinking approach to improving research practices," said Chasse.

Chasse and Pierre agree that it is becoming increasingly difficult for independent research practices to leverage the economies of scale necessary to be successful. A network of research sites, they say, provides ways to keep sites busier and guarantee high-quality end results while assuring positive patient experiences.

RxTrials has eight research sites located in five states, all of which are located within clinical practices or hospitals.  "Adam will provide RxTrials with strategic site development and study placement opportunities focused on our clients' needs," said Pierre.

"RxTrials' vision for expanding opportunities for patients and physicians to take part in important research is identical to mine, so I feel we're a perfect fit," said Chasse.

"It's so expensive to take a drug through the research process, which has been further complicated by the fact that pharma companies are looking at rarer diseases than they were 10 years ago. Therefore, it's more difficult to run a trial in the same period of time partly because it's harder to find enough patients," said Chasse. "On top of that, study designs are getting more complex and investigators are being challenged to recruit more patients while adding procedures and tests. Plus, there is more scrutiny of data by Sponsors and FDA."

"What Sponsors and physicians need is an entity that can help them navigate that process," added Pierre.

"Christine is an innovator and recognized leader in the industry. She has the respect of everyone who knows her. Hers is one of the very few site networks that emerged since 1990 that is still not only around but thriving," said Chasse.

"The deal was recently closed and not yet publically announced and I've already fielded calls from colleagues in the industry. It seems good news travels fast," said Pierre.

About RxTrials, Inc.

RxTrials is a network of premier Investigative Sites based in physician practices and hospitals that conduct Phase II through Phase IV and vaccine clinical research studies. Since 1994, RxTrials has successfully completed more than 1,000 studies and is a strategic partner with leading Sponsors and CROs.  Its affiliate, RxTrials Institute, provides professional training, education and consultation, and sponsors the annual Site Solutions Summit.

Interviews and print-quality images of the logo and personnel are available upon request.


'/>"/>
SOURCE RxTrials, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RxTrials Earns National Women-Owned Business Certification
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... and ANN ARBOR, Mich. ... held biopharmaceutical company developing breakthrough immune modulatory medicines, announced ... of the Company,s lead therapeutic candidate, LYC-30937- E nteric ... often a debilitating skin disease that is estimated to ... the United States , with approximately 1.5 - ...
(Date:12/7/2016)... Boston, MA and Azusa, CA (PRWEB) , ... ... ... commercial provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, ... Brewing Company , will be the first to use Cambrian’s novel water-energy purchase ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA ... shopping cart. The new website has been designed to provide the best user-friendly ... customers to access detailed product information, read educational industry content as well as ...
(Date:12/7/2016)... Woods Hole, Massachusetts (PRWEB) , ... December 07, 2016 , ... Kara Dwyer Dodge grew ... 1966, Richard Dwyer, a third-generation fisherman in Scituate, Mass., found a sea turtle entangled in ... to shore, where the turtle became a minor sensation because no one could remember ever ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):